Plasma or serum levels of syndecan-1 on admission were found to be significantly elevated in patients with severe and critical COVID-19, which appears to be associated with mortality, intensive care unit (ICU) admission, and multiple organ damage [11,15,16,17,18,19]. Here, SDC1 is linked to COVID-19.